Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Financial press releases

06 January 2015

Sight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total € 18.5 million funding for SIGHT AGAIN as part of the Investment for the Future

06 May 2014

GenSight Biologics appoints Jean-Philippe Combal as Chief Operating Officer

08 April 2013

GenSight Biologics announced today the closing of a €32 million Series A financing for Ophthalmic Gene Therapy.

  • View previous 9 articles
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page